Pustular psoriasis: pathophysiology and current treatment perspectives.

Benjegerdes KE, et al. Psoriasis (Auckl). 2016;6:131-144.

Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial.

Bissonnette R, et al. J Eur Acad Dermatol Venereol. 2014;28(10):1298-1305.

Generalized pustular psoriasis—a model disease for specific targeted immunotherapy, systematic review.

Boehner A, et al. Exp Dermatol. 2018;27(10):1067-1077.

Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia.

Choon SE, et al. Int J Dermatol. 2014;53(6):676-684.

Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis.

Hagforsen E, et al. Br J Dermatol. 2010;163(3):572-579.

Generalized pustular psoriasis: a review and update on treatment.

Hoegler KM, et al. J Eur Acad Dermatol Venereol. 2018;32(10):1645-1651.

Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis.

Marrakchi S, et al. N Engl J Med. 2011;365(7):620-628.

What do we know about palmoplantar pustulosis?

Misiak-Galazka M, et al. J Eur Acad Dermatol Venereol. 2017;31(1):38-44.

Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum.

Murakami M, et al. Exp Dermatol. 2011;20(10):845-847.

Palmoplantar psoriasis and palmoplantar pustulosis: current treatment and future prospects.

Raposo I, Torres T. Am J Clin Dermatol. 2016;17(4):349-358.

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J).

Saeki H, et al. J Dermatol. 2017;44(4):355-362.

The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: a systematic review.

Sanchez IM, et al. Dermatol Ther (Heidelb). 2017;7(4):425-446.

Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.

Sano S, et al. J Dermatol. 2018;45(5):529-539.

The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants.

Sugiura K. J Dermatol Sci. 2014;74(3):187-192.

Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial.

Terui T, et al. JAMA Dermatol. 2018;154(3):309-316.

Clinical and genetic differences between pustular psoriasis subtypes.

Twelves S, et al. J Allergy Clin Immunol. 2018. [Epub ahead of print].

Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.

Yamasaki K, et al. Br J Dermatol. 2017;176(3):741-751.